The oncogene MYBL2 (encoding B-Myb) is a poor prognostic biomarker in many cancers. B-Myb interacts with the MuvB core of five proteins (LIN9, LIN37, LIN52, LIN53/RBBP4, and LIN54) to form the MMB (Myb-MuvB) complex and promotes expression of late cell cycle genes necessary for progression through mitosis. Both MYBL2 amplification and over-expression are associated with deregulation of the cell cycle and increased cell proliferation. Alternatively, by interacting with E2F4-DP1 and p130 or p107, the MuvB core becomes part of the DREAM complex (DP, RB-like, E2F, and MuvB). The DREAM complex opposes MMB by globally repressing cell cycle genes in G0/G1, maintaining the cell in a quiescent state. However, the specific mechanism by which B-Myb alters the cell cycle is not well understood. Our analysis of The Cancer Genome Atlas data revealed significant upregulation of DREAM and MMB target genes in breast and ovarian cancer with MYBL2 gain. Given that most of the DREAM target genes are not directly regulated by B-Myb, we investigated the effects of B-Myb on DREAM formation. We found that depletion of B-Myb results in increased DREAM formation in human cancer cells, while its overexpression inhibits DREAM formation in the non-transformed cells. Since the MuvB core subunit LIN52 is essential for assembly of both the DREAM and MMB complexes, we tested whether B-Myb disrupts DREAM by sequestering LIN52. Overexpression of LIN52 did not increase either DREAM or MMB formation, but instead increased the turnover rate of the endogenous LIN52 protein. Interestingly, co-expression of B-Myb increased the expression of both endogenous and overexpressed LIN52 while knockdown of B-Myb had an opposite effect. We found that regulation of LIN52 occurs at the protein level, and that activity of DYRK1A kinase, the enzyme that triggers DREAM complex formation by phosphorylating LIN52, is required for this regulation. These findings are the first to implicate B-Myb in the disassembly of the DREAM complex and offer insight into the underlying mechanisms of poor prognostic value of MYBL2 amplification in cancer. We conclude that B-Myb mediates its oncogenic effects not only by increasing mitotic gene expression by the MMB complex, but also by broad disruption of cell cycle gene regulatory programs through compromised DREAM formation.
Introduction
Since its discovery in 1988, several studies have established MYBL2 (encoding B-Myb) as a clinically important oncogene. 1, 2 Indeed, MYBL2 is part of the commercially available Oncotype DX ® screening panel and validated DCIS (Ductal Carcinoma in situ) Score TM , used to clinically predict the risk of local recurrence in patients with breast cancer. 3, 4 Although B-Myb is a well-recognized biomarker, particularly in breast cancer, the specific cellular mechanisms of its oncogenic activities are not fully understood.
Previous studies characterized B-Myb as a transcription factor involved in cell cycle regulation, present in almost all proliferating cells. 5 Furthermore, B-Myb is essential for cell proliferation, as evidenced by failure of inner cell mass formation and early embryonic death of MYBL2 knock-out mice. 6 Deregulation of cell cycle gene expression is one of B-Myb's oncogenic properties. [7] [8] [9] Studies in Drosophila and human cells revealed that B-Myb regulates transcription as part of evolutionarily conserved multi-subunit protein complexes sharing common subunits with DNA-binding complexes formed by retinoblastoma (RB) family members. 10 In Drosophila, Myb regulates expression of developmental and cell cycle genes by associating with the dREAM (RB, E2F, and Myb) complex. This complex also includes five proteins homologous to the products of the C. elegans multi-vulva class B (MuvB) genes: LIN9, LIN37, LIN52, LIN53/RBBP4 and LIN54. 11, 12 In the mammalian cell cycle, the DREAM (DP, RB-like, E2F, and MuvB) complex is important for modulating gene expression by repressing more than 800 cell cycle genes (including MYBL2) in quiescent cells. 13 It is assembled in G0/G1 when the MuvB subunit, LIN52, is phosphorylated at serine-28 (S28) by DYRK1A (dual-specificity tyrosine-phosphorylation regulated kinase 1A), bringing together RB-like p130 and the MuvB core of five proteins. 14 Cell cycle progression occurs when p130 is phosphorylated by cyclindependent kinases and dissociates from MuvB. 15 MuvB then binds B-Myb in the S phase, forming the MMB (Myb-MuvB) complex. MMB formation is necessary for G2/M gene expression by FOXM1 and is therefore associated with increased mitotic activity. 16, 17 Importantly, LIN52 is required for the MuvB core to bind B-Myb, making LIN52 an essential component of both the DREAM and MMB complexes. 15 Unlike the S28 phosphorylation requirement for DREAM assembly, LIN52 binding to B-Myb is phosphorylation-independent.
Notably, a recent study found that MMB complex formation is necessary for lung tumor formation and drives cellular proliferation through expression of mitotic kinesins. 8 Additionally, several MMB downstream target genes are included in a chromosomal instability signature (CIN) used as a predictor of outcomes in multiple cancer types. [18] [19] [20] Despite these findings, the specific mechanism of deregulated cell cycle gene expression by B-Myb remains elusive.
Studies of DREAM disruption show that DREAM-deficient cells are unable to maintain quiescence and have MMB complex levels comparable to proliferative cells, despite signals for cell cycle arrest. 21 The phenotype of DREAM disruption thus closely resembles that of B-Myb over-expression. 22, 23 These results support the idea of mandatory MMB complex formation when DREAM is unable to assemble and also suggest that B-Myb, when over-expressed, plays a causal role in disrupting DREAM. When DREAM is inactivated by genetic mutations in mice, abnormal binding of B-Myb to MuvB during the G1 phase of the cell cycle correlates with loss of DREAM target gene repression, leading to cell cycle deregulation. 21 Since MYBL2 is a target gene suppressed by DREAM, it is difficult to determine whether or not B-Myb overexpression in cancer disrupts DREAM or if DREAM disruption occurs by other mechanisms, then leading to enhanced B-Myb expression. Therefore, we investigated the regulation of DREAM by B-Myb as a potential mechanism for the cell cycle defects observed in cancers with high B-Myb levels. We show that increased expression of B-Myb disrupts DREAM by recruitment of LIN52 to the MMB complex, compromising repression of DREAM-targeted cell cycle genes. These findings implicate global cell cycle deregulation as a means by which B-Myb exerts its oncogenic effects.
Results

B-Myb regulates DREAM
High B-Myb level is associated with compromised DREAM formation and function.
To test our hypothesis that B-Myb disrupts DREAM, we first looked at microarray data from The Cancer Genome Atlas (TCGA) to determine the relationship between B-Myb level and cell cycle gene expression. We chose to focus on high grade serous ovarian carcinoma (HGSOC), since it exhibits a high prevalence of MYBL2 amplification or gain (55%) and represents a cancer type in which B-Myb is associated with a poor prognosis ( Fig. 1A, 1S ). 24 Similar analyses were conducted in parallel for breast cancer, for which the significance of B-Myb overexpression is well-documented ( Fig. 1S) . [25] [26] [27] [28] [29] [30] [31] As expected, we found that high B-Myb levels are associated with increased MMB target gene expression. Furthermore, expression of DREAM target genes were also significantly upregulated in the tumor samples with high B-Myb expression (Fig. 1C) , and the top 50 most differentially expressed genes in this cohort have been previously annotated as DREAM target genes ( Fig. 1D, 1S ). 13 Given these results, we used SKOV3 serous ovarian carcinoma cells (with MYBL2 gene amplification) to investigate mechanisms of how B-Myb modulates DREAM complex formation. 32 In asynchronously growing SKOV3 cells, DREAM exists at low steady state levels and RNAi-mediated knock-down of B-Myb enhances DREAM formation ( Fig. 2A) . RT-qPCR analysis revealed decreased expression of representative DREAM target genes (FOXM1 and CCNB2) upon B-Myb knockdown, in agreement with the observed increase of the DREAM formation ( Fig.   2B ). [33] [34] [35] The effects of B-Myb gain of function on DREAM formation were subsequently assessed by expressing HA-B-Myb in non-transformed human foreskin fibroblasts immortalized with hTERT (BJ-hTERT).
We hypothesized that high B-Myb levels could impede DREAM assembly, thus overexpression of B-Myb should suppress DREAM regardless of environmental signals favoring DREAM formation. Indeed, in the cells that were serum-starved to induce cell cycle arrest and DREAM assembly, less p130 coimmunoprecipitated with a shared MuvB complex protein, LIN37, in the presence of B-Myb overexpression as compared to cells expressing the control vector (HA-GFP) ( Fig. 2C) . Consistent with this finding, we also observed a significantly greater proliferation rate of HA-B-Myb cells compared to control cells ( Fig. 2D) .
Collectively, the data support a model in which B-Myb, when present at high levels, interferes with DREAM formation and function, altering cell cycle gene expression programs. Furthermore, evidence of MMB formation under conditions that normally favor DREAM assembly suggests that B-Myb achieves DREAM disruption by binding to MuvB.
LIN52 regulation
LIN52 is regulated at the protein level.
Since LIN52 is required for the interaction between either B-Myb or p130 with MuvB core, we next wanted to determine if increasing availability of LIN52 by ectopic overexpression could rescue DREAM formation in the presence of HA-B-Myb. Therefore, we transduced BJ-hTERT fibroblasts expressing HA-B-Myb, (shown in Figure 2C) , with retrovirus to express LIN52-V5. Control BJ-hTERT cells as well as cells expressing HA-B-Myb alone, or together with LIN52-V5, were treated with the CDK4/6 inhibitor, palbociclib, to encourage DREAM formation. 15 As shown in Figure 3A , DREAM assembly was enhanced with palbociclib treatment in control cells, but not in the cell lines with ectopic expression of HA-B-Myb. At the same time, inappropriate MMB formation was also observed in the presence of palbociclib treatment.
Interestingly, these effects persisted in BJ-hTERT cells in which LIN52-V5 was co-expressed with HA-B-Myb even with palbociclib treatment, suggesting that highly expressed B-Myb could sequester LIN52 (and MuvB) away from p130 under these conditions. It is also possible that the overall availability of the MuvB core did not increase upon ectopic expression of LIN52. In support of this conclusion, the amount of coprecipitated LIN9 remained the same as in control cells despite more LIN52 co-immunoprecipitated with LIN37 from LIN52-V5-expressing cells. Furthermore, the amount of the endogenous LIN52 bound to LIN37 in the presence of LIN52-V5 was markedly reduced, indicating that availability of other subunits could limit the formation of MuvB.
To clarify this finding, we used the cell lines described in Figure 2C to detect changes in LIN52 protein by direct Western blot. Indeed, LIN52 was more abundant in HA-B-Myb-expressing cells in the presence of serum, and there was a decrease in the endogenous LIN52 protein levels when ectopic LIN52-V5 was expressed ( Fig. 3B) . Since LIN52 is a DREAM target gene and high B-Myb expression is associated with DREAM disruption, it is possible that upregulation of LIN52 is due to transcriptional derepression. In support of this model, we found that B-Myb and steady state LIN52 protein levels are tightly correlated. When B-Myb was overexpressed in BJ-hTERT cells, LIN52 was also more abundant, and the opposite effect was observed upon B-Myb knock-down in SKOV3 cells ( Fig. 3C, D) . Collectively, these results led us to investigate changes in LIN52 levels as a potential mechanism by which B-Myb impacts DREAM assembly.
We have previously characterized T98G cells stably expressing a LIN52 mutant S28A in which DREAM formation is diminished. 14 This substitution abolishes the DYRK1A-phosphorylation site essential for DREAM formation without interfering with the MMB complex assembly. 15 Interestingly, endogenous LIN52 protein was similarly down-regulated in T98G cell lines expressing the wild type LIN52-V5 or LIN52-S28A-V5, as compared to the empty vector control cells ( Fig. 4A) . Furthermore, RT-qPCR with primers designed for the 3' untranslated (UTR) region shows no significant changes in endogenous LIN52 mRNA resulting from ectopic LIN52 expression, suggesting these observations are due to protein-level regulation ( Fig. 4B) . In support of this conclusion, ectopically expressed LIN52-V5 levels were tightly regulated by overexpression or knockdown of B-Myb in T98G cells (Fig. 2S) .
These findings prompted further investigations into LIN52 protein regulation using a Global Protein Stability (GPS) approach. 36 In this method, the protein of interest (LIN52) is fused with GFP and expressed as a single mRNA transcript together with an internal control marker (DsRed). During translation, an internal ribosome entry site in the GPS transcript allows for the production of LIN52-GFP and DsRed proteins ( Fig.   4C ). By monitoring the relative fluorescence intensities of GFP and DsRed, LIN52 abundance is measured in living cells. 36, 37 T98G glioblastoma cells were chosen for these studies as they have been used extensively in cell cycle research, including initial characterization of the DREAM complex. They also represent a cancer cell line lacking MYBL2 amplification, making them amenable to both loss and gain of function studies of B-Myb. 13, 14, 16, [38] [39] [40] [41] [42] Using direct immunofluorescence and immunoblotting, we observed that although LIN52-S28A fusion protein was expressed at a slightly higher level than wild-type LIN52, both proteins were expressed at dramatically lower levels than control GFP alone. The dsRed expression levels were comparable in these cell lines, indicating that LIN52 fusion proteins are unstable. To determine whether LIN52 fusion proteins are degraded by proteasome, we treated the GPS-T98G cell lines with MG-132 for 6 hours. Addition of MG-132 increased LIN52-GFP abundance but had no effect on the corresponding S28A fusion, implicating LIN52 phosphorylation in the regulation of LIN52 protein level and the ubiquitin-proteasome pathway in LIN52 degradation ( Fig. 4D) . However, since inhibition of the proteasome by MG-132 or mutation of the serine 28 residue in LIN52 failed to fully restore LIN52 fusion protein level to that of the control GFP, it is likely that additional factors govern LIN52 level. Combined with our observations shown in Figures 3C, D, perhaps B-Myb is one of these factors.
We next directly compared the stability of the endogenous LIN52, wild-type LIN52-V5, and S28A mutant LIN52-V5 using cycloheximide (CHX) chase experiments with T98G stable cell lines. Quantification of three independent CHX chase experiments revealed a significant decrease in wild-type LIN52-V5 level relative to the S28A mutant after 3 hours of CHX treatment (Figs. 4E, F) . Furthermore, although endogenous LIN52 was expressed at lower levels compared to the LIN52-V5 proteins, it showed greater stability than ectopically expressed wild type LIN52. As before, we noted a decrease in endogenous LIN52 protein levels resulting from its rapid degradation in the presence of ectopic LIN52 proteins. RT-qPCR analysis using primers designed to detect the LIN52 open reading frame (ORF) showed no significant difference between LIN52-V5 and LIN52-S28A-V5 mRNA expression ( Fig. 4G) , further confirming the predominance of protein level regulation. Additionally, we noted that while LIN52 was depleted over the course of 6h, two other MuvB proteins (LIN9 and LIN37) remained relatively stable ( Fig. 4E) . This result indicates that LIN52 could be differentially regulated among the other MuvB proteins.
Together, these results demonstrate that LIN52 is regulated at the protein level. Therefore, the changes observed in LIN52 level with depletion or overexpression of B-Myb ( Fig. 3B-D) are likely due to protein-level regulation of LIN52 by B-Myb, and not by B-Myb-mediated disruption of the DREAM repression.
Furthermore, these findings indicate that LIN52 level may be part of the mechanism by which B-Myb alters DREAM and MMB formation.
B-Myb regulates LIN52 level.
To further investigate the role of B-Myb in regulation of LIN52, the effect of B-Myb expression on LIN52 protein stability was initially examined in a series of quantitative cycloheximide chase experiments. Figures 5A and B (Fig. 5E) . Interestingly, in the same series of experiments, we found that B-Myb exhibits no significant effect on LIN52-S28A-V5 protein level. Since B-Myb is still able to bind to LIN52-S28A-V5, these results suggest that phosphorylation at the serine 28 residue is also regulating LIN52 levels.
As shown in
DYRK1A-mediated phosphorylation contributes to regulation of LIN52 stability.
Since we previously demonstrated that LIN52 phosphorylation at serine 28 residue is mediated by DYRK1A, we used CRISPR/Cas9 to generate T98G cells devoid of DYRK1A protein (DYRK1A-KO) ( Fig.   4S ). Additionally, we treated intact T98G cells with a DYRK1A kinase inhibitor, harmine (10µM for 20h). As shown in Figure 6A , LIN52 was expressed at higher steady-state levels and appeared in a predominantly un-phosphorylated (faster migrating) form in DYRK1A knock-out cells or with harmine treatment, consistent with lack of DYRK1A activity ( Fig. 6A) . Furthermore, CHX chase experiments confirmed that stability of endogenous LIN52 was enhanced when DYRK1A is absent or inhibited by harmine ( Figs. 6B and C) .
Interestingly, RT-qPCR analysis of the DYRK1A-KO or harmine-treated T98G cells revealed a modest increase in LIN52 mRNA expression when DYRK1A is knocked out or inhibited ( Fig. 6D) suggesting that LIN52 is also regulated by DYRK1A at the level of transcription. To further determine the importance of DYRK1A in regulating LIN52 protein, we used RNAi to deplete DYRK1A in T98G cells expressing either V5tagged wild-type or S28A mutant LIN52. We found that while a stabilization effect was observed in wild-type LIN52 upon DYRK1A knock-down, expression of S28A mutant was unchanged, further supporting the role of DYRK1A in regulation of LIN52 protein stability (Figs. 6E and F). Taken together, our data demonstrate that LIN52 is regulated at the protein level by B-Myb and DYRK1A-dependent phosphorylation, as well as at the transcriptional level by DYRK1A.
B-Myb is highly expressed in cancers with LIN52 loss or DYRK1A gain.
We hypothesized that high B-Myb expression is a compensatory mechanism for maintaining proliferation in tumors with LIN52 loss or DYRK1A gain. 43, 44 To test this model, high grade serous ovarian carcinoma TCGA data was queried for co-occurrence of MYBL2 gene copy number gain with losses or gains in the LIN52 or DYRK1A genes, and analyzed using cBioPortal.org tools. 45 In support of our model, mutual exclusivity analysis showed a significant chance of co-occurrence of MYBL2 copy number gain with either loss of LIN52, or gain of DYRK1A, in the same tumor sample ( Fig. 7A) . 
5A-D).
Discussion
Our data show that a gene expression signature of DREAM complex inactivation is present in breast and ovarian cancers with high expression of B-Myb, and that the DREAM complex is disrupted in human cells when B-Myb is highly expressed. B-Myb is overexpressed in many types of cancer and is recognized as a poor prognostic factor, but the known role of B-Myb as a transcription factor required for mitotic progression does not fully explain its established association with a more aggressive cancer phenotype. Furthermore, our studies presented here describe for the first time the complexity by which LIN52, the key MuvB component required for assembly of both DREAM and MMB, is regulated. LIN52 is tightly regulated at the protein level. Ectopic LIN52 expression results in increased turnover of both the endogenous and ectopically expressed protein. We also show that, while S28-phosphorylation-dependent proteasomal degradation plays a role in LIN52 protein turnover, this is clearly not the only mechanism that regulating its protein levels. Indeed, proteasomal inhibition or S28A mutation could only modestly increase the expression of the GFP-LIN52 fusion proteins in the GPS dual reporter system (Fig. 4C) . Given a highly stable association of the MuvB subunits within the complex, it is possible that several MuvB subunits must be expressed together so they can be properly folded and stabilized. It will be interesting to determine whether this additional, phosphorylation-independent mechanism could involve cellular chaperone complexes, such as CCR4-NOT, that mediate degradation of misfolded proteins or products of aberrantlyexpressed mRNA. Perhaps these cellular chaperone complexes play a role in maintaining the proper levels of MuvB core subunits in the cell. Therefore, further studies are needed to investigate these possible mechanisms.
We also demonstrate that B-Myb overexpression leads to de-repression of DREAM cell cycle gene targets (Figs. 1D, 2B) . Since MYBL2 itself is a DREAM target gene, this might create a positive feedback loop in which B-Myb overexpression drives further B-Myb expression and perpetuates DREAM disruption. 46 This is also relevant to HPV-positive cancers with E7-mediated DREAM complex disassembly. [46] [47] [48] [49] [50] Indeed, T98G cells expressing viral oncoproteins have higher amounts of B-Myb and MMB as compared to cells with intact DREAM. 51, 52 B-Myb was also identified as a target for E7-mediated transcriptional activation, leading to inappropriate expression of B-Myb in G1 and higher steady state levels in cycling cells, mimicking our model of B-Myb overexpression. 53 Clinical evidence supports these studies by showing that E7 expression correlates with B-Myb levels and mitotic gene expression in cervical cancer. 54, 55 Together, these studies provide a support to mechanisms whereby E7 and B-Myb cooperate to increase MMB formation and mitotic gene expression at the expense of pocket protein/DREAM activity. Furthermore, E7
has been shown to disrupt the interaction between LIN52 and the p130/p107, supporting the importance of LIN52 in mediating DREAM and MMB formation. 56 LIN52 is required for both DREAM and MMB formation and directly interacts with p130/p107 in vitro, but is insufficient for co-precipitation of B-Myb. Therefore, other MuvB components are also important for mediating MMB formation and perhaps LIN52 mainly serves to preserve MuvB integrity. 15 This is supported by diminished co-immunoprecipitation of MuvB complex components when LIN52 is depleted by shRNA. 14 However, other studies have shown that B-Myb, LIN37, and LIN54 are also diminished when LIN9 is depleted, suggesting that there is no significant free pool of these proteins and they form a stable complex in the S phase. 57 Another recent study revealed compromised DREAM repressor function upon LIN37 loss, but MMB function remained intact and the remaining MuvB subunits were able to interact with either p130, or B-Myb in the LIN37 knockout cells. A MuvB-binding deficient mutant LIN37 was unable to rescue DREAM, demonstrating the importance of MuvB integrity for DREAM assembly. 58 In combination, these findings highlight the complexity of MuvB regulation and suggest that MuvB components may be differentially regulated depending on their participation in either DREAM or MMB. We have shown that LIN52 levels in the cell are tightly controlled and regulated by B-Myb and DYRK1A. Together, these findings suggest that regulation of LIN52 stability may be central to maintaining MuvB and alterations in LIN52 stability, in turn, a potential determining factor for which complex (DREAM or MMB) forms. We have previously shown that B-Myb and p130 can bind MuvB simultaneously, so direct competition for binding is unlikely. 15 However, if LIN52 is crucial to the integrity of MuvB, then B-Myb may hold a competitive advantage over p130 through its stabilization of LIN52 (Fig. 5) .
The same phosphorylation event resulting in DREAM assembly is also associated with LIN52 degradation (Fig. 6) . 14 This suggests LIN52 degradation is a cooperative process between the DREAM complex and another factor, such as an E3 ligase. Previous proteomics data identified several candidate E3 ligases associated with the DREAM complex that may play a part in LIN52 degradation. 13, 14 Determination of the particular E3 ligase responsible for LIN52 degradation would be valuable to further understand the regulation of the DREAM and MMB complexes. 8 Finally, several of the MMB downstream targets upregulated in late S-G2 phases of the cell cycle, such as Aurora kinase A, Polo-like kinase B and others have been proposed for developing anti-cancer therapies. 8, 59 Better understanding of the mechanisms that bring about high expression of these genes in cancer will be important to inform the future pre-clinical and clinical studies and to optimize patient stratification. Overall, we have shown a novel model describing some of the molecular processes underlying deregulated cell cycle gene expression in cancers with B-Myb amplification or overexpression. These findings argue that B-Myb is not only a negative prognostic factor through increased MMB formation and activation of the mitotic gene expression program, but also through decreased DREAM assembly and loss of repression of more than 800 cell cycle-regulated genes. Further studies with tumor samples are needed to validate our model in patients.
Cell lines
Parental cell lines were purchased through the American Type Culture Collection. T98G cells stably expressing V5-tagged LIN52 or LIN52-S28A were previously produced by retroviral gene transfer. 13, 14 These cells were, in turn, infected with a HA-FLAG-B-Myb pMSCV-NTAP retroviral vector made previously by Gateway cloning and selected in media containing 1ug puromycin. BJ-hTERT cells were infected with the same HA-FLAG-B-Myb pMSCV-NTAP retroviral vector or a matching GFP-HA-FLAG control vector. 13 BJ-hTERT cells co-expressing both HA-FLAG-BMYB and LIN52-V5 were made in the same manner as the corresponding T98G cells described above. The LIN52-GFP and LIN52-S28A-GFP constructs were generated in GPS-pHAGE vectors and subsequently used to produce stable T98G cell lines. 5´-ACTTTCACACAACTACAGC-3´). PCR products were sequenced to confirm the presence of mutation at the targeted site. Since we received sequences with multiple lesions, we wanted to rule out the presence of a mixed clone and to confirm the presence of single cell clones. TA cloning was performed using Promega pGEM®-T Easy Vector Systems followed by transformation according to manufacturer's protocol. White colonies (n=21) were isolated for each clone, allowed to grow on 96-well plates overnight, replica-plated and sent for hi-throughput sequencing using a T7 primer.
Antibodies
Antibodies for MuvB complex components LIN9, LIN37, and LIN52 (Bethyl Inc.) were previously described in Litovchick et al. 2007 . 13 
Growth assay
ATPLite 1,000 assay kit (PerkinElmer, 6016941) was used according to the manufacturer's protocol. For each cell line, 3,000 cells were plated per well and luminescence was measured at days 3 and 5.
Real-time and quantitative PCR
RNA extractions were performed with TRIzol reagent (Invitrogen) and was reverse transcribed using SensiFAST TM cDNA Synthesis kit (Bioline). The resulting cDNA was used for qPCR with Maxima SYBR Green/ROX Mastermix (2X) (ThermoFisher, K022) and the following primers:
Primers
Sequences ( Applied Biosystems 7900HT was used for detection and fold changes in mRNA expression relative to controls were calculated using the 2DDCt methodology.
Drugs
The following were obtained from Sigma-Aldrich: Cycloheximide (3-[ (C) Fluorescence cell imaging of T98G cells expressing GPS control, or GPS-LIN52 fusion constructs reveal decreased signal of GFP reporter fused to LIN52 compared to control, but not of the dsRed reporter protein.
(D) WB analysis confirms the expression of the GFP-LIN52 fusion proteins at a lower level than GFP alone.
Cells were treated with MG-132 for 6h to inhibit proteasomal degradation. Note that S28A mutation increases the expression of the GFP-LIN52 fusion protein (but not to the GFP-control levels). (E) WB analysis of cycloheximide (CHX) chase experiment using T98G stable cell lines expressing empty vector, LIN52-V5 or LIN52-S28A-V5 mutant. One set of cells collected at 6h was treated with both CHX and MG-132 to assess proteasomal degradation. Note differential rates of degradation of LIN9, LIN37, as well as endogenous and ectopic LIN52. (F) Quantification of data from three independent CHX chase experiments using T98G cell lines expressing LIN52-V5 or LIN52-S28A-V5 mutant. Graph shows average ± stdev (* -Student's t-test p<0.05).
(G) RT-qPCR analysis shows similar expression of the wild-type and S28A-mutant LIN52 mRNA. Graph shows average ± stdev of three independent experiments (ns -Student's t-test p>0.05). 
